Risk assessment and prediction of TD incidence in psychiatric patients taking concomitant antipsychotics: a retrospective data analysis

Oscar Patterson-Lomba¹, Rajeev Ayyagari¹ and Benjamin Carroll²*

Abstract

Background: Tardive dyskinesia (TD) is a serious, often irreversible movement disorder caused by prolonged exposure to antipsychotics; identifying patients at risk for TD is critical to preventing it. Predictive models for the occurrence of TD can improve patient monitoring and inform implementation of counteractive interventions. This study aims to identify risk factors associated with TD and to develop a model using a retrospective data analysis to predict the incidence of TD among patients taking antipsychotic medications.

Methods: Adult patients with schizophrenia, major depressive disorder, or bipolar disorder taking oral antipsychotics were identified in a Medicaid claims database (covering six US states from 1997 to 2016) and divided into cohorts based on whether they developed TD within 1 year after the first observed claim for antipsychotics. Patient characteristics between cohorts were compared, and univariate Cox analyses were used to identify potential TD risk factors. A cross-validated version of the least absolute shrinkage and selection operator regression method was used to develop a parsimonious multivariable Cox proportional hazards model to predict diagnosis of TD.

Results: A total of 189,415 eligible patients were identified. Potential TD risk factors were identified based on the cohort analysis within a sample of 151,280 patients with at least 1 year of continuous eligibility. The prediction model had a clinically meaningful concordance of 70% and was well calibrated ($P = 0.32$ for Hosmer–Lemeshow goodness-of-fit test). Age (hazard ratio [HR] = 1.04, $P < 0.001$), diagnosis of schizophrenia (HR = 1.99, $P < 0.001$), antipsychotic dosage (up to 100 mg/day chlorpromazine equivalent; HR = 1.65, $P < 0.01$), and comorbid bipolar and related disorders (HR = 1.39, $P < 0.01$) were significantly associated with an increased risk of TD. Other potential risk factors included history of extrapyramidal symptoms (HR = 1.35), other movement disorders (parkinsonism, HR = 1.43; bradykinesia, HR = 1.44; tremors, HR = 2.12, and myoclonus, HR = 2.33), and diabetes (HR = 1.13). A modest reduction in the risk of TD was associated with the use of second-generation antipsychotics (HR = 0.85) versus first-generation drugs.

Conclusions: This study identified factors associated with development of TD among patients taking antipsychotics. The prediction model described herein can enable physicians to better monitor patients at high risk for TD and recommend appropriate treatment plans to help maintain quality of life.

Keywords: Tardive dyskinesia, Risk factors, Psychiatric patients, antipsychotics, Prediction model, Least absolute shrinkage and selection operator
Background
Tardive dyskinesia (TD) is a hyperkinetic, potentially irreversible movement disorder that is typically caused by prolonged exposure to antipsychotic drugs [1–6]. The clinical manifestations include abnormal movements of the face, lips, tongue, cheeks, jaws and extremities, and severity of symptoms can range from mild to disabling and potentially life-threatening [1, 2, 6–9]. Besides the physical discomfort experienced due to the disease, the involuntary, repetitive and pronounced nature of TD symptoms can exacerbate the stigmatization often already faced by patients with mental illness, leading to social alienation, behavioral disturbances and nonadherence [2, 3, 5, 10].

Motor side effects have been reported in as many as 40% of patients receiving antipsychotics; thus, elucidation of both modifiable and nonmodifiable risk factors for TD susceptibility remains a research priority [4, 11]. An increased risk for developing TD has been associated with older age, female sex, underlying mental disorders, history of extrapyramidal symptoms (EPS), diabetes, and higher antipsychotic dose and longer duration of exposure to antipsychotics [7, 12–15]. Several studies also suggest a higher risk for TD incidence with the use of first-generation (typical) compared with second-generation (atypical) antipsychotic drugs [4, 7, 16]. A 2008 review reported annual TD incidence rates in adults of 3.0% with second-generation antipsychotics versus 7.7% with first-generation antipsychotics [17]. In contrast, results from various groups show similar frequencies of TD occurrence regardless of the class of antipsychotic drug treatment, and that movement disorders associated with newer antipsychotic drugs are not clinically negligible when taking into consideration methodological differences (e.g. study population, clinical setting and differential diagnosis) that can potentially lead to the underestimation of incidence in patients treated with second-generation antipsychotics [18–20]. Therefore, no consensus currently exists on the exact epidemiology of TD [17, 19, 20].

Prevention and treatment of TD continue to pose significant challenges to clinicians [2, 20]. First, detection of TD onset can be delayed due to inconsistent clinical presentations, significant variability in developmental timelines, masking of symptoms by the very drugs that cause TD, and misclassification of motor symptoms as medication-induced side effects [1, 3, 5, 9, 19, 21]. Even after a definitive diagnosis is made, the lowering or cessation of treatment with causative drugs may be contraindicated due to aggravation of psychosis and other symptoms of underlying comorbidities in TD patients [2, 6, 19]. Furthermore, considering that TD is sometimes irreversible, early diagnosis or withdrawal from antipsychotic therapy may confer only partially ameliorative benefits [3, 21].

Although novel drugs for treatment have been recently approved for TD [22], the best management strategy should include better monitoring and implementation of risk-stratified prophylactic measures, such as the modification of treatment plans for patients at risk of developing TD [2, 4, 23]. Further investigation for potential risk factors to identify “true predictors” of disease is warranted to accurately identify high-risk populations [3, 11]. In the current study, we developed and validated a predictive model assessing the combined effect of clinical characteristics on TD risk, which, to our knowledge, is the first of its kind for US populations. The resulting prediction model has the potential to guide decision-making regarding treatment and follow-up management.

Methods

Study objective and data sources
A retrospective cohort study was conducted to identify risk factors and develop a model to predict the incidence of TD among psychiatric patients taking antipsychotic medication. Medicaid claims data from a database that represented a sample of the total Medicaid beneficiaries in the US from six states (Iowa, Kansas, Missouri, New Jersey, Mississippi and Wisconsin) were extracted. The claims data included services provided (for most states) from 1997 through the first quarter of 2016. Complete medical claims (e.g. procedures, paid amounts and diagnoses), pharmaceutical claims, enrollment history, and patient demographics were available for analysis from the Medicaid records. The most recent 6 years of data (varies by state) were used for this analysis.

Patient selection
Patients with schizophrenia, major depressive disorder, or bipolar disorder, who were taking antipsychotic medications and who also satisfied the following eligibility criteria were selected from Medicaid claims database (the most recent 6 years of data of each state): at least two diagnoses for schizophrenia (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] codes: 295.xx; International Classification of Diseases, Tenth Revision, Clinical Modification [ICD-10-CM] codes: F20.x), major depressive disorder (296.2, 296.3; F32.xx, F33.xx), or bipolar disorder (296.0, 296.1, 296.4–296.8; F31.x); at least one oral antipsychotic fill (see Additional file 1 ICD-9-CM and ICD-10-CM Codes for Selected Comorbidities and GPIs for Antipsychotics) after first observed diagnosis for the underlying disorder and before any observed TD diagnosis (333.81, 333.82, 333.85; G24.01, G24.4, G24.5); ≥18 years of age at index date (date of the first observed antipsychotic fill); a baseline period of continuous eligibility for ≥6 months before the index date; and cases with daily doses that are not missing nor daily dose outliers (i.e. daily dose > 1,200
mg/day chlorpromazine equivalent [24–26]). Patients from New Jersey who turned 65 after 2012 were dual-eligible for Medicare and Medicaid and thus excluded from the study to eliminate the possibility of incomplete capture of their drug claim information. The study period was defined from the index date to the end of eligibility or end of data. There was no minimum time requirement for post-index eligibility.

Patients characteristics and study variables
The following patient information was collected: demographics (age, gender, state, and health plan); disease duration (from first observed diagnosis of schizophrenia, or depression, or bipolar disorder to index date); index antipsychotic treatment by class (i.e. the treatment the patients were treated with on the index date, which can be a first-generation antipsychotic, a second-generation antipsychotic, both or none); comorbidity profile, including psychiatric comorbidities, Charlson Comorbidity Index (CCI) score (a method of categorizing comorbidities based on ICD codes, where each comorbidity category has a weight associated to its risk of mortality or resource use, and the sum of the weights results in a single score) [27, 28]; brain damage, diabetes, dementia, Parkinsonism, and other selected comorbidities; EPS other than TD, e.g. akathisia, parkinsonism, dystonia, and tremors; cognitive disabilities such as Down’s syndrome, autism, dyslexia and other scholastic disorders; traumatic brain injury; smoking history and alcohol abuse; diabetes; and duration of follow-up (see Additional file 1 ICD-9-CM and ICD-10 CM Codes for Selected Comorbidities and GPs for Antipsychotics). The main outcome was time to TD diagnosis after index date.

Risk factor identification
Patients with at least 1 year of continuous eligibility after their index date were divided into two cohorts: those who developed TD within 1 year, and those who did not develop TD within 1 year. Patient characteristics were then compared between the two cohorts to identify potential risk factors for TD. Means and standard deviations were summarized for continuous variables, whereas frequencies and percentages were summarized for categorical variables. Statistical comparisons were conducted using Wilcoxon rank-sum tests for continuous variables, McNemar’s test for dichotomous variables, and chi-squared tests for categorical variables. For mutually exclusive categorical variables with more than two categories, the statistical comparisons were conducted using Bowker’s test for symmetry.

Univariate Cox regression models were also used to assess the association of each patient baseline characteristic with the risk of TD diagnosis among all selected patients. Time to event was estimated as the period from index date to the first TD claim. Patients without the event of interest during the study period were censored at the end of their follow-up period.

Development and validation of predictive model
Data were separated randomly into a modeling set (two-thirds of the data), used to develop and parametrize the prediction model, and a validation set (one-third of the data), used to test out-of-sample performance of the prediction model.

A multivariable Cox proportional hazard model was developed using the modeling set to predict the time to TD diagnosis in patients taking antipsychotics at a given time point after the index date. The variables in the model included the aforementioned patient characteristics as potential predictors based on the univariate Cox models and “TD” versus “no TD” cohort comparisons. Based on the non-linear empirical relationships between the probability of TD diagnosis with age and dose, predictors used also included transformed dose and age variables. Covariates in the model (before selection) were: age at index date; sex; index diagnosis; type of index antipsychotic; history and number of EPS; dose, transformed dose (as a continuous effect for doses up to 100 mg/day of chlorpromazine equivalents, and as a continuous effect for doses larger than 100 mg/day of chlorpromazine equivalents); CCI; comorbid movement disorders, including parkinsonism, akathisia, bradykinesia, tremors, and myoclonus; comorbid psychiatric disorders, including anxiety disorders, depressive disorders, bipolar and related disorders; and other factors, including brain damage, dementia, diabetes, and alcohol history. Interactions between underlying type of mental disorder and treatment patterns, or between sex and age were also included in the model. The least absolute shrinkage and selection operator (LASSO) regression method was used to simultaneously estimate the model and identify the patient characteristics that better predicted TD. The model was selected to minimize a cross-validated prediction error, which helped to avoid overfitting and to enhance the interpretability of the model. A Cox regression was then performed with only the selected covariates from the LASSO regression to obtain HR estimates and the corresponding P value associated with each of the model variables. Risk factors for TD were then characterized based on effect size and significance.

Predictive performance was assessed in the validation set by: 1) model discrimination or concordance, which is the ability of the model to distinguish between low and high-risk patients, quantified by the C statistics (C = 0.5 is random prediction, and C = 1 is perfect prediction); and 2) model calibration, which determines the
agreement between the observed and predicted risk of TD at any given time after the index date, quantified by the Hosmer-Lemeshow goodness-of-fit test ($P > 0.05$ suggests a good fit to the data, i.e. good calibration). The Breslow estimator of the baseline hazard was combined with the HRs to obtain predicted risks of TD for each patient at 2 years after the index date.

**Results**

**Baseline characteristics by diagnosis**

A total of 189,415 patients met the inclusion criteria in the Medicaid claims database used (see Additional file 2 Sample Selection Flow Chart). Patient characteristics and treatment history are summarized for all patients and by initial psychiatric diagnosis in Table 1. Briefly, the mean age of all patients was 42.8 years (bipolar, 39.6 years; depressive disorder, 43.9 years; schizophrenia, 45.4 years); 38.1% of all patients were men (bipolar, 32.6%; depressive disorder, 28.7%; schizophrenia, 56.9%); the overall average daily dose of antipsychotic medication was 220 mg chlorpromazine equivalent (bipolar, 211 mg; depressive disorder, 157 mg; schizophrenia, 309 mg). The vast majority of all patients (86.7%) were prescribed a second-generation antipsychotic at index date (bipolar, 91.3%; depressive disorder, 88.8%; schizophrenia, 81.4%). The comorbidity profiles were different among the three diagnostic groups; patients with schizophrenia showed the lowest CCI scores, as well as lower rates of substance-related and addictive disorders, anxiety disorders, personality disorders, trauma- and stressor-related disorders, brain damage, and smoking history.

**Comparison of baseline characteristics by TD cohort**

A sample of 151,280 patients with at least 1 year of continuous eligibility after the index date was used to identify potential risk factors of TD. A total of 381 patients developed TD within 1 year and were classified as ‘TD’; and the remaining 150,899 patients who did not develop TD within 1 year were labeled as ‘No TD.’ Age, diagnosis of schizophrenia, use of first-generation antipsychotics, antipsychotic dose, CCI, diabetes, and incidence of EPS-related comorbidities were significantly higher at baseline in the ‘TD’ cohort than in the ‘No TD’ cohort. The characteristics that were significantly different between the two cohorts are shown in Table 2.

**Identification of TD predictors using univariate Cox analyses**

Univariate Cox analysis was conducted in the full sample of 189,415 patients to identify potential risk factors for TD in psychiatric patients taking concurrent antipsychotic medication (Table 3). The results suggest associative relationships between TD onset and mostly the same baseline risk factors identified by the cohort analysis described above (Table 2). According to the univariate Cox model, a significant increase in risk of TD was found to be associated with diagnosis of schizophrenia (HR = 1.96 compared with bipolar), antipsychotic dose (up to 100 mg/day of chlorpromazine, HR = 1.91), dementia (HR = 2.04), EPS-related comorbidities (number of EPS, HR = 1.91; history of EPS, HR = 2.37) and diabetes (HR = 1.52). A small but significant association was determined for CCI (HR = 1.06) and age (HR = 1.04). Compared with first-generation antipsychotics, use of second-generation antipsychotics, use of first- and second-generation antipsychotics (data not shown).
## Table 1: Patient demographics and baseline characteristics by diagnosis

| Patient characteristics | Total N = 189,415 | Bipolar disorder N = 66,723 | Depressive disorder N = 68,573 | Schizophrenia N = 54,119 |
|-------------------------|-------------------|-----------------------------|-------------------------------|------------------------|
| **Demographics**        |                   |                             |                               |                        |
| Age (years)             | 42.8 ± 13.8       | 39.6 ± 13.0                 | 43.9 ± 13.8                   | 45.4 ± 13.9           |
| Male, % (n)             | 38.1% (72,187)    | 32.6% (21,749)              | 28.7% (19,662)                | 56.9% (30,776)        |
| HMO Plan, % (n)        | 20.3% (38,494)    | 21.2% (14,133)              | 20.8% (14,227)                | 18.7% (10,134)        |
| **State**               |                   |                             |                               |                        |
| Iowa                    | 8.1% (15,390)     | 10.8% (7,226)               | 7.8% (5,366)                  | 5.2% (2,798)          |
| Kansas                  | 8.3% (15,698)     | 8.8% (5,851)                | 8.0% (5,469)                  | 8.1% (4,378)          |
| Mississippi             | 8.9% (16,756)     | 7.1% (4,741)                | 9.5% (6,539)                  | 10.1% (5,476)         |
| Missouri                | 38.7% (73,293)    | 38.9% (25,924)              | 43.3% (29,694)                | 32.7% (17,675)        |
| New Jersey              | 21.5% (40,667)    | 19.1% (12,737)              | 18.5% (12,659)                | 28.2% (15,271)        |
| Wisconsin               | 14.6% (27,611)    | 15.4% (10,244)              | 12.9% (8,846)                 | 15.7% (8,521)         |
| Observed disease duration (months) | 7.8 ± 13.0 | 7.6 ± 12.8 | 9.2 ± 13.6 | 6.2 ± 12.2 |
| Duration of follow-up (months) | 38.6 ± 24.6 | 37.4 ± 23.8 | 32.6 ± 23.5 | 47.8 ± 24.2 |
| **Index AP use**        |                   |                             |                               |                        |
| First generation        | 10.4% (19,673)    | 7.4% (4,958)                | 10.6% (7,239)                 | 13.8% (7,476)         |
| Multiple                | 2.0% (3,849)      | 1.2% (818)                  | 0.7% (448)                    | 4.8% (2,583)          |
| Second generation       | 87.6% (165,893)   | 91.3% (60,947)              | 88.8% (60,886)                | 81.4% (44,060)        |
| Chlorpromazine equivalent daily dose (100 mg/day) | 2.2 ± 2.1 | 2.1 ± 1.9 | 1.6 ± 1.6 | 3.1 ± 2.4 |
| **Psychiatric comorbidities** |             |                             |                               |                        |
| Substance-related and addictive disorders | 23.8% (45,014) | 27.1% (18,090) | 26.2% (17,944) | 16.6% (8,980) |
| Anxiety disorders       | 21.9% (41,438)    | 23.0% (15,322)              | 31.5% (21,603)                | 8.3% (4,513)          |
| Autism                  | 0.6% (1,149)      | 0.9% (614)                  | 0.4% (258)                    | 0.5% (277)            |
| Bipolar and related disorders | 32.6% (61,715) | 77.9% (51,959) | 9.8% (6,743) | 5.6% (3,013) |
| Depressive disorders    | 45.2% (85,537)    | 24.3% (16,195)              | 90.2% (61,862)                | 13.8% (7,480)         |
| Personality disorders   | 4.0% (7,526)      | 4.6% (3,045)                | 4.6% (3,168)                  | 2.4% (1,313)          |
| Schizophrenia spectrum disorders (excluding schizophrenia) | 8.2% (15,550) | 6.1% (4,094) | 6.6% (4,511) | 12.8% (6,945) |
| Sleep-wake disorders    | 8.5% (16,024)     | 8.8% (5,838)                | 11.4% (7,845)                 | 4.3% (2,341)          |
| Trauma- and stress- or related disorders | 10.0% (19,004) | 10.8% (7,178) | 14.4% (9,883) | 3.6% (1,943) |
| **Other comorbidities** |                   |                             |                               |                        |
| CCI                     | 0.6 ± 1.2         | 0.5 ± 1.1                   | 0.7 ± 1.4                     | 0.4 ± 1.0             |
| Alcohol history         | 7.7% (14,592)     | 8.2% (5,461)                | 8.7% (5,958)                  | 5.9% (3,173)          |
| Brain damage            | 1.0% (1,790)      | 0.8% (563)                  | 1.3% (885)                    | 0.6% (342)            |
| Dementia                | 1.6% (3,080)      | 0.9% (624)                  | 2.0% (1,392)                  | 2.0% (1,064)          |
| Diabetes                | 14.0% (26,600)    | 11.6% (7,767)               | 16.4% (11,215)                | 14.1% (7,618)         |
| Down's Syndrome         | 0.1% (200)        | 0.1% (67)                   | 0.1% (84)                     | 0.1% (49)             |
| Dyslexia and other scholastic disorders | 0.1% (254) | 0.1% (68) | 0.2% (123) | 0.1% (63) |
| Smoking history         | 13.7% (25,927)    | 16.2% (10,793)              | 15.1% (10,337)                | 8.9% (4,797)          |
| Traumatic brain injury  | 0.4% (673)        | 0.3% (207)                  | 0.5% (317)                    | 0.3% (149)            |
| **Extrapyramidal symptoms** |             |                             |                               |                        |
| Akathisia               | 0.1% (248)        | 0.1% (94)                   | 0.1% (90)                     | 0.1% (64)             |
| Bradykinesia            | 3.3% (6,251)      | 3.0% (1,973)                | 4.2% (2,308)                  | 2.5% (1,370)          |
| Dystonia                | 0.1% (167)        | 0.1% (60)                   | 0.1% (34)                     | 0.1% (73)             |
| EPS (unspecified)       | 0.8% (1,430)      | 0.8% (559)                  | 0.9% (636)                    | 0.4% (235)            |
The variability observed in the onset, developmental pattern, and response to interventional treatment make TD a difficult condition to diagnose and to treat [3, 5, 9]. Because TD is sometimes irreversible, early detection and prevention of TD in patients with high-risk status is an important strategy for the clinical management of TD [3, 11, 21].

Despite recent advances, identification of TD predictors remains challenging for researchers and clinicians [1]. There are common methodological confounding factors and considerable study limitations, including that TD can mimic signs of the underlying comorbidity or that it can be masked by antipsychotics [1, 3, 4, 19, 21]. In the current study, the use of large claims data provided real-world evidence for the incidence of TD due to antipsychotic medication use among patients with schizophrenia, major depressive disorder, or bipolar disorder. Furthermore, the analytical approach was designed to help identify risk factors for TD by examining their associations with TD diagnosis both in isolation and in combination with a large set of factors via multivariate modeling, which, to our knowledge, had not previously been developed or validated in US populations.

Consistent with prior studies [7, 12–15], of the baseline and index-date characteristics under consideration, that it can be masked by antipsychotics [1, 3, 4, 19, 21]. In the current study, the use of large claims data provided real-world evidence for the incidence of TD due to antipsychotic medication use among patients with schizophrenia, major depressive disorder, or bipolar disorder. Furthermore, the analytical approach was designed to help identify risk factors for TD by examining their associations with TD diagnosis both in isolation and in combination with a large set of factors via multivariate modeling, which, to our knowledge, had not previously been developed or validated in US populations. Consistent with prior studies [7, 12–15], of the baseline and index-date characteristics under consideration,

### Table 1 Patient demographics and baseline characteristics by diagnosis (Continued)

| Patient characteristics | Total N = 189,415 | Bipolar disorder N = 66,723 | Depressive disorder N = 68,573 | Schizophrenia N = 54,119 |
|-------------------------|------------------|-----------------------------|-------------------------------|--------------------------|
| Myoclonus               | 0.1% (120)       | 0.1% (37)                   | 0.1% (64)                     | 0.04% (19)               |
| Malignant neuroleptic syndrome | 0.02% (46)     | 0.02% (13)                  | 0.01% (4)                     | 0.1% (29)                |
| Parkinsonism            | 0.1% (141)       | 0.1% (34)                   | 0.1% (31)                     | 0.1% (76)                |
| Drug-induced tics       | 0.0% (7)         | 0.0% (3)                    | 0.01% (4)                     | 0.0% (0)                 |
| Tremors                 | 0.3% (490)       | 0.3% (183)                  | 0.3% (222)                    | 0.2% (85)                |
| History of EPS          | 4.3% (8,063)     | 4.0% (2,663)                | 5.4% (3,668)                  | 3.2% (1,732)             |
| Number of EPS           | 0.1 ± 0.2        | 0.04 ± 0.23                 | 0.1 ± 0.3                     | 0.04 ± 0.21              |

**AP** antipsychotic, **CCI** Charlson Comorbidity Index, **EPS** extrapyramidal symptoms, **HMO** health maintenance organization, **TD** tardive dyskinesia

### Table 2 Patient demographics and baseline characteristics by TD cohort

| Patient characteristics | TD N = 381 | No TD N = 150,899 | P value |
|-------------------------|------------|-------------------|---------|
| Age (years)             | 51.4 ± 13.2| 43.3 ± 13.6       | < 0.001 |
| Index Diagnosis, %/n    |            |                   |         |
| Bipolar disorder        | 24.2% (92) | 35.2% (53,169)    |         |
| Depressive disorder     | 21.8% (83) | 33.3% (50,213)    | < 0.001 |
| Schizophrenia           | 54.1% (206)| 31.5% (47,517)    |         |
| Generation of index AP  |            |                   |         |
| First generation        | 16.8% (64) | 10.5% (15,850)    |         |
| Multiple                | 3.4% (13)  | 2.3% (3,424)      | < 0.001 |
| Second generation       | 79.8% (304)| 87.2% (131,625)   |         |
| Chlorpromazine equivalent daily dose (100 mg/day) | 2.78 ± 2.29 | 2.29 ± 2.11 | < 0.001 |
| CCI                     | 0.64 ± 1.18| 0.53 ± 1.16       | 0.05    |
| Diabetes                | 23.9% (91) | 14.4% (21,674)    | < 0.001 |
| Bipolar and related disorders | 26.0% (99) | 31.9% (48,075) | < 0.05 |
| Depressive disorders    | 32.6% (124)| 42.6% (64,301)    | < 0.001 |
| Bradykinesia            | 9.7% (37)  | 3.3% (4,917)      | < 0.001 |
| Dystonia                | 0.8% (3)   | 0.1% (131)        | < 0.001 |
| Myoclonus               | 1.1% (4)   | 0.1% (91)         | < 0.001 |
| Parkinsonism            | 0.8% (3)   | 0.1% (119)        | < 0.001 |
| History of EPS          | 12.3% (47) | 4.2% (6,388)      | < 0.001 |
| Number of EPS           | 0.14 ± 0.41| 0.05 ± 0.23       | < 0.001 |

**AP** antipsychotic, **CCI** Charlson Comorbidity Index, **EPS** extrapyramidal symptoms, **TD** tardive dyskinesia
Table 3 Hazard ratio for risk factors using variables selected by the LASSO method

| Patient characteristics | Univariate Cox analyses | Variables selected by the LASSO method |
|-------------------------|-------------------------|--------------------------------------|
|                         | Hazard Ratio            | 95% CI                               | P value | Hazard ratio | 95% CI | P value |
| Age (years)             | 1.04 (1.03, 1.04)       | < 0.001                              |         | 1.04 (1.03, 1.04) | < 0.001 |
| Square root of age      | 1.72 (1.60, 1.84)       | < 0.001                              |         |             |        |        |
| Age less than 65 indicator | 0.33 (0.27, 0.41)   | < 0.001                              |         |             |        |        |
| Index Diagnosis vs. Bipolar Disorder | | | | | | |
| Depressive Disorder | 0.95 (0.78, 1.14)       | 0.57                                 | 1.02    | (0.79, 1.32) | 0.88  |
| Schizophrenia           | 1.96 (1.67, 2.29)       | < 0.001                              | 1.99    | (1.57, 2.53) | < 0.001 |
| Generation of Index AP vs. First generation | | | | | | |
| Multiple                | 0.88 (0.58, 1.33)       | 0.54                                 | 0.80    | (0.52, 1.21) | 0.29  |
| Second generation       | 0.72 (0.59, 0.87)       | < 0.001                              | 0.85    | (0.70, 1.03) | 0.09  |
| Dose (continuous effect for dose ≤ 100 mg/day of chlorpromazine) | 1.91 (1.38, 2.66) | < 0.001 | 1.65 (1.17, 2.31) | < 0.01 |
| Dose (continuous effect for dose > 100 mg/day of chlorpromazine) | 1.05 (1.02, 1.08) | < 0.01 |             |        |        |
| CCI                     | 1.06 (1.00, 1.12)       | < 0.05                               |         |             |        |        |
| Depressive disorders    | 0.78 (0.68, 0.89)       | < 0.001                              |         |             |        |        |
| Bipolar and related disorders | 0.84 (0.72, 0.97) | < 0.05 | 1.39 (1.11, 1.75) | < 0.01 |
| Dementia                | 2.04 (1.38, 3.01)       | < 0.001                              |         |             |        |        |
| Diabetes                | 1.52 (1.29, 1.79)       | < 0.001                              | 1.13    | (0.96, 1.34) | 0.14  |
| Number of EPS           | 1.91 (1.60, 2.29)       | < 0.001                              |         |             |        |        |
| History of EPS          | 2.37 (1.88, 2.99)       | < 0.001                              | 1.35    | (0.74, 2.47) | 0.33  |
| Parkinsonism            | 4.29 (1.38, 13.33)      | < 0.05                               | 1.43    | (0.44, 4.72) | 0.55  |
| Bradykinesia            | 2.48 (1.92, 3.21)       | < 0.001                              | 1.44    | (0.77, 2.68) | 0.25  |
| Tremors                 | 3.93 (1.96, 7.89)       | < 0.001                              | 2.12    | (0.97, 4.60) | 0.06  |
| Myoclonus               | 4.27 (1.07, 17.11)      | < 0.05                               | 2.33    | (0.56, 9.7) | 0.25  |

AP antipsychotic, CCI Charlson Comorbidity Index, CI confidence interval, EPS extrapyramidal symptoms, LASSO least absolute shrinkage and selection operator

Fig. 1 Kaplan-Meier curves of time to TD diagnosis. Estimated TD incidence rate within 7 years after antipsychotic drug initiation were stratified by index psychiatric disorder diagnosis. TD, tardive dyskinesia
patient age, diagnosis of schizophrenia, dosage of antipsychotic medication (up to 100 mg/day of chlorpromazine equivalent), and presence of bipolar and related disorders were associated with greater risk of TD in patients taking antipsychotics. Interestingly, the presence of bipolar and related disorders was found to be associated with a significant decrease in the risk of TD in the univariate analyses, but this association was reversed in the multivariate model, indicating the importance of examining these associations while accounting for other factors. Also, female sex, a variable previously observed to be associated with an increased risk of TD [11, 29], was not among the best predictors of TD in this study.

Although the relationship we found between predictors included in this study and TD diagnosis was associative rather than causal in nature, these observations are clinically relevant findings that can aid in risk-mitigation planning and implementation. The resulting prediction model can provide the risk or probability that TD will occur within any time period after the index date (e.g. 1 or 2 years) for each patient based on their baseline or index-date prognostic factors, which can guide decision-making regarding treatment and follow-up management from the time of the diagnosis of the psychiatric disorder.

There has been considerable debate regarding the attribution in TD incidence since widespread adoption of second-generation antipsychotics. One study previously reported a point prevalence of 13% with second-generation antipsychotics versus 32% with first-generation, whereas other studies have reported no differences [19, 30–32]. In addition, multiple studies have challenged the notion that second-generation antipsychotics are relatively free of the risk of TD [19, 20]. The current study utilized univariate and multivariate Cox models to re-assess the comparative risk of TD associated with both drug classes. Compared with first-generation antipsychotics, the use of second-generation antipsychotics was associated with a statistically significant reduction in the risk of TD when analyzed using a univariate Cox model. However, this reduction was more modest and no longer significant in the final LASSO prediction model.

Limitations

Although the study yielded a well-calibrated prediction model with a clinically meaningful concordance of 71%, it was subject to limitations that are inherent to using a claims database. The study population was limited to patients within the Medicaid database and represented only six US states, and therefore its findings may not be generalizable to other patient populations. TD was relatively rare in this study population (the KM-estimated proportion of patients with TD at 7 years after antipsychotic drug initiation was less than 2%), which is partly due to a relatively short follow-up period for the condition under study. As a result, the prediction performance of the model, in terms of its discrimination power (concordance), was acceptable rather than excellent. This issue was mitigated by using the LASSO methodology, which can provide better predictions than standard regression by avoiding overfitting in data sets with few events. In addition, comorbidities may have been underestimated because they were identified using diagnosis codes, which are typically used for administrative purposes. Although the data set used in this analysis provides a large and representative real-world evidence of patients in the US, it spans a limited follow-up time (up to 7 years), which is an important limitation given that the development of TD is associated with long-term use of antipsychotics. Thus, the rate of TD claims in these data was low compared with the prevalence of TD, which is 20–50% among all patients treated with antipsychotics [9]. Another likely limitation of the study is that, due to its observational design, results may have been confounded due to unobserved factors that cannot be accounted for in multivariable regression analyses. For example, this study did not examine the role of race/ethnicity in the risk of TD, which was previously identified as a potential risk factor [13]. Also, given the
large number of antipsychotic medications and the relatively low number of TD events observed in these data, the risk of TD was analyzed by class of antipsychotics and not by each antipsychotic separately. Thus, the risk of TD associated with each specific antipsychotic was not ascertained in this analysis.

The paucity of claims for TD in the database, in comparison with the reported prevalence for motor disorder of up to 40% reported previously [4], may affect the prognostic implications of the findings reported herein. One possibility is that the constraints of a retrospective study design may lead to underestimation of TD prevalence [33]. However, the discrepancy between observed and anticipated TD prevalence rates in the study may underscore a more-systemic problem regarding the epidemiology of TD, namely the potential underreporting due to a lack of clinical awareness or standardization of diagnostic criteria [34].

Conclusions
This study identified a group of factors associated with the development of TD among patients who had psychiatric disorders treated with antipsychotics. The prediction model developed and validated herein can help physicians identify patients at high risk for TD in order to develop treatment and monitoring plans that help patients maintain their quality of life.

Additional files

**Additional file 1:** ICD-9-CM and ICD-10-CM codes for selected comorbidities and GPIs for antipsychotics. (DOCX 37 kb)

**Additional file 2:** Sample selection flow chart. (DOCX 635 kb)

Abbreviations
CCI: Charlson Comorbidity Index; EPS: Extrapyramidal symptoms; GPI: Generic Product Indicator; HR: Hazard ratio; ICD-10-CM: International Classification of Diseases, Tenth Revision, Clinical Modification; ICD-9-CM: International Classification of Diseases, Ninth Revision, Clinical Modification; KM: Kaplan–Meier; LASSO: Least absolute shrinkage and selection operator; TD: Tardive dyskinesia

Acknowledgments
We thank Aprita Biswas, PhD (Chameleon Communications International with funding from Teva Pharmaceuticals) for editorial assistance in the preparation of this report. We also thank Sophie Schonfeld and Monica Macheca (Analysis Group, Inc.) for helpful discussions and support with the statistical analyses.

Authors’ contributions
All authors were involved in the design of the study, interpretation of the data, writing of the manuscript, and the decision to submit the manuscript for publication. All authors read and approved the final manuscript.

Funding
This study was funded by Teva Pharmaceuticals, Petach Tikva, Israel. Analysis Group, Inc. received payment from Teva Pharmaceuticals to conduct research.

Availability of data and materials
The data that support the findings of this study are available from Analysis Group, but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are, however, available from the authors upon reasonable request and with permission of Analysis Group.

Ethics approval and consent to participate
The New England Independent Review Board approved this project as an exempted retrospective study and determined that informed consent was not required.

Consent for publication
Not applicable.

Competing interests
OPL is an employee of Analysis Group, Inc. RA is an employee of Analysis Group, Inc. BC is an employee of Teva Pharmaceuticals.

Author details
1Analysis Group, Inc., 111 Huntington Avenue, Boston, MA 02199, USA. 2Teva Pharmaceuticals, 41 Moores Rd, Malvern, PA 19355, USA.

Received: 22 February 2019 Accepted: 1 July 2019
Published online: 20 July 2019

References
1. Aquino CC, Lang AE. Tardive dyskinesia syndromes: current concepts. Parkinsonism Relat Disorders. 2014;20(Suppl 1):S113–S7. https://doi.org/10.1016/S1353-8020(13)70028-2.
2. Lerner PP, Miadowski C, Lerner V. Tardive dyskinesia (syndrome): current concept and modern approaches to its management. Psychiatry Clin Neurosci. 2015;69(1):23–34. https://doi.org/10.1111/pcn.12270.
3. Jain R, Correll CU. Tardive dyskinesia: recognition, patient assessment, and differential diagnosis. J Clin Psychiatry. 2018;2. https://doi.org/10.4088/JCP. nu17054ah1c.
4. Stegmayer K, Walther S, van Harten P. Tardive dyskinesia associated with atypical antipsychotics: prevalence, mechanisms and management strategies. CNS Drugs. 2018;32(2):135–47. https://doi.org/10.1007/s40263-018-0409-8.
5. Tany D, Baldessarini RJ. Tardive dyskinesia. Annu Rev Med. 1984;35:605–23. https://doi.org/10.1146/annurev.me.35.020184.003133.
6. Connell EM, Novitch M, Kaye AD, Kata V, Kaye AW. Medication-induced tardive dyskinesia: a review and update. Ochsner J. 2017;17(2):162–74.
7. Rana AQ, Chaudry ZM, Blanchet PJ. New and emerging treatments for symptomatic tardive dyskinesia. Drug Des Devel Ther. 2013;7:1329–40. https://doi.org/10.2147/DDDT.S32328.
8. Savitt D, Jankovic J. Tardive syndromes. J Neurol Sci. 2018;389:35–42. https://doi.org/10.1016/j.jns.2018.02.005.
9. Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (N Y). 2013. https://doi.org/10.7916/D88PSZ71.
10. Mathews M, Gratz S, Adetunji B, George V, Mathews M, Basil B. Antipsychotic-induced movement disorders: evaluation and treatment. Psychiatry (Edmont). 2005;2(3):36–41.
11. Solmi M, Pigato G, Kane JM, Correll CU. Clinical risk factors for the development of tardive dyskinesia. J Neurol Sci. 2018;389:21–7. https://doi.org/10.1016/j.jns.2018.02.012.
12. Chouinard G, Annable L, Ross-Chouinard A, Mercier P. A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases. J Clin Psychopharmacol. 1988;8(Suppl 2):215–65. https://doi.org/10.1097/00004844-198811002-00021.
13. Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications: results of the Yale tardive dyskinesia study. Arch Gen Psychiatry. 1993;50(9): 723–33.
14. Tenback DE, van Harten PN, Scoff CJ, van Os J. Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Am J Psychiatry. 2006;163(8):1438–40. https://doi.org/10.1176/appi.ajp.2006.163.8.1438.
15. Tenback DE, van Harten PN, van Os J. Non-therapeutic risk factors for onset of tardive dyskinesia in schizophrenia: a meta-analysis. Mov Disord. 2009; 24(16):2309–15. https://doi.org/10.1002/mds.22707.

16. Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord. 2006;21(15):589–98. https://doi.org/10.1002/mds.20823.

17. Correll CU, Schenck EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry. 2008;21(2):151–6. https://doi.org/10.1097/YCO.0b013e328f33132.

18. Caroff SN, Hurford I, Lybrand J, Campbell EC. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. Neurol Clin. 2011;29(1):127–48. viii. https://doi.org/10.1016/j.ncl.2010.10.002.

19. D’Abreu A, Akbar U, Friedman JH. Tardive dyskinesia: epidemiology. J Neurol Sci. 2018;389:17–20. https://doi.org/10.1016/j.jns.2018.02.007.

20. Martino D, Morgante F. Movement disorders and chronic psychosis. Neurol Clin Pract. 2017;7(2):163.

21. Caroff SN, Ungvary GS, Cunningham Owens DG. Historical perspectives on tardive dyskinesia. J Neurol Sci. 2018;389:4–19. https://doi.org/10.1016/j.jns.2018.02.015.

22. Teva Pharmaceutical Industries Ltd. Teva Announces FDA approval of AUSTEDO® (deutetrabenazine) tablets for the treatment of tardive dyskinesia in adults. 2017. http://www.tevapharm.com/news/teva_announces_fda_approval_of_austedo_deutetrabenazine_tablets_for_the_treatment_of_tardive_dyskinesia_in_adults_08_17.aspx. Accessed 31 Jan 2019.

23. Touma KTB, Scarff JR. Valbenazine and deutetrabenazine for tardive dyskinesia. Innov Clin Neurosci. 2018;15(5–6):13–6.

24. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003;64(6):663–7.

25. Atkins M, Burgess A, Bottomley C, Riccio M. Chlorpromazine equivalents: a consensus of opinion for both clinical and research applications. Psychiatr Bull. 1997;21(4):224–6. https://doi.org/10.1092/pb.1997.21.4.224.

26. Leucht S, Samara M, Herness S, Patel MX, Woods SW, Davis JM. Dose equivalents for second-generation antipsychotics: the minimum effective dose method. Schizophr Bull. 2014;40(2):314–26. https://doi.org/10.1093/ schbul/sbu001.

27. Charlson ME, Pompei P, Ales KL, CR MK. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–8. https://doi.org/10.1016/0021-9681(87)90171-8.

28. de Groot V, Beckerman H, Lankhorst GJ, Bouter LM. How to measure comorbidity. A critical review of available methods. J Clin Epidemiol 2003;56:221–229.

29. Yassa R, Jeste DV. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull. 1992;18(4):701–15.

30. Miller DD, Caroff SN, Davis SM, Rosenheck RA, McEvoy JP, Saltz BL, et al. Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry. 2008;193(4):279–88. https://doi.org/10.1192/bjp.bp.108.050088.

31. Peluso MJ, Lewis SW, Barnes TR, Jones PR. Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs. Br J Psychiatry. 2012;200(5):387–92. https://doi.org/10.1192/bjp.bp.111.101485.

32. Woods SW, Morgenstern H, Saksa JR, Walsh BC, Sullivan MC, Money R, et al. Incidence of tardive dyskinesia with atypical and conventional antipsychotic medications: prospective cohort study. J Clin Psychiatry. 2010;71(4):463–74. https://doi.org/10.4088/JCP.07m03890yel.

33. Zuzghi D, Cloud LJ, Factor SA. Tardive syndromes are rarely reversible after discontinuing dopamine receptor blocking agents: experience from a univeristy-based movement disorder clinic. Tremor Other Hyperkinet Mov (N Y). 2014;4:226. https://doi.org/10.7916/D8MS53RB.

34. Cortese L, Jorg M, McAuley TJ, Kotteva V, Costa G. Assessing and monitoring antipsychotic-induced movement disorders in hospitalized patients: a cautionary study. Can J Psychiatr. 2004;49(1):31–6. https://doi.org/10.1177/070674370404900105.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.